Acerus Pharmaceuticals Performance
| ASPCFDelisted Stock | USD 0.22 0.00 0.00% |
The firm shows a Beta (market volatility) of -3.39, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Acerus Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Acerus Pharmaceuticals is expected to outperform it. Acerus Pharmaceuticals right now shows a risk of 0.0%. Please confirm Acerus Pharmaceuticals standard deviation and the relationship between the treynor ratio and day typical price , to decide if Acerus Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acerus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental indicators, Acerus Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 9.2 M | |
| Total Cashflows From Investing Activities | -16 K |
Acerus |
Acerus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 22.00 in Acerus Pharmaceuticals on January 20, 2024 and sell it today you would earn a total of 0.00 from holding Acerus Pharmaceuticals or generate 0.0% return on investment over 90 days. Acerus Pharmaceuticals is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded otc stocks are less volatile than Acerus, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Acerus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acerus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Acerus Pharmaceuticals, and traders can use it to determine the average amount a Acerus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ASPCF |
Based on monthly moving average Acerus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acerus Pharmaceuticals by adding Acerus Pharmaceuticals to a well-diversified portfolio.
Acerus Pharmaceuticals Fundamentals Growth
Acerus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Acerus Pharmaceuticals, and Acerus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acerus OTC Stock performance.
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 | |||
| Operating Margin | (8.41) % | |||
| Current Valuation | 49.66 M | |||
| Shares Outstanding | 7.71 M | |||
| Price To Book | 20.08 X | |||
| Price To Sales | 2.16 X | |||
| Revenue | (4.13 M) | |||
| EBITDA | (31.5 M) | |||
| Cash And Equivalents | 1.29 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 21.14 M | |||
| Debt To Equity | 2.61 % | |||
| Book Value Per Share | (1.80) X | |||
| Cash Flow From Operations | (23.52 M) | |||
| Earnings Per Share | (3.63) X | |||
| Total Asset | 9.65 M | |||
About Acerus Pharmaceuticals Performance
To evaluate Acerus Pharmaceuticals OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Acerus Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Acerus OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Acerus Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Acerus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for mens and womens health. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. ACERUS PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 14 people.Things to note about Acerus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Acerus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Acerus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acerus Pharmaceuticals is not yet fully synchronised with the market data | |
| Acerus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Acerus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company has accumulated 21.14 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. Acerus Pharmaceuticals has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Acerus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acerus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acerus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acerus to invest in growth at high rates of return. When we think about Acerus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (33.82 M) with profit before overhead, payroll, taxes, and interest of 1 M. | |
| Acerus Pharmaceuticals has accumulated about 1.29 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. | |
| Roughly 91.0% of Acerus Pharmaceuticals shares are held by company insiders |
- Analyzing Acerus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acerus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acerus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acerus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acerus Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Acerus Pharmaceuticals' otc stock. These opinions can provide insight into Acerus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Acerus OTC Stock
If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |